ORTEXORTEX News
Tracking AXTI? Get live short interest, options flow, and signals on ORTEX.Sign up free →
AX
Earnings PreviewAXTI

AXTI Q2 Print: Bulls Bet on Recovery While Bears Hold 24% of the Float

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 27 Jul 2026, 03:54

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

AXT, Inc. heads into Wednesday's Q2 earnings with competing signals sharper than almost any other small-cap print this quarter — a heavily shorted stock, a conspicuously bullish options market, and a mean analyst target that is roughly double the current price.

The short position remains the dominant fact of the setup. Bears hold 24.4% of the free float — 10.9 million shares — a level that has edged down from the July 17 peak of 11.75 million but still reflects a 55% build over the past month. The short score has tracked the same slow retreat, easing from 57.5 on July 17 to 52.2 now, suggesting bears are trimming rather than adding in the final days before the report. Crucially, they are doing so voluntarily: borrow availability has loosened further to 419%, meaning roughly four shares sit idle in the lending pool for every one borrowed, and cost to borrow is a negligible 0.45%. There is no squeeze pressure forcing anyone's hand.

Options positioning has diverged sharply from the short book. The put/call ratio has dropped to 0.52, more than one standard deviation below its 20-day average of 0.69. That marks a pronounced shift — as recently as late June, the PCR was running above 1.0, signalling heavy downside hedging. The rotation toward calls over the past two weeks reads as growing conviction among some investors that the stock has overshot to the downside. At $47.23, AXTI has shed 39% over the past month and roughly 59% from its late-May peak near $141. The July 24 session alone cost shareholders 10.8%. Correlated peers fell sharply on the same day — TSEM lost 10.4%, AEHR fell 13.8%, GFS dropped 5.9% — framing at least part of AXTI's decline as sector-wide rather than company-specific.

The analyst debate is stark. Wedbush has maintained an Outperform rating and raised its target three times since February, most recently to $93 after the Q1 beat. The bull case centres on AXT's position as a key supplier of indium phosphide substrates for AI and data centre optical interconnects, a market management has projected growing 4x–6x over the next several years. The bear case, represented by B. Riley and Needham (both at Neutral/Hold), points to heavy revenue concentration in China, ongoing export licensing exposure, and the reality that a PE ratio near 83x leaves no room for execution stumbles. The mean consensus target of $96.50 sits more than double the current price — a gap that itself becomes part of the story, either as a valuation opportunity or as evidence the Street has not yet caught up with the structural risks the stock market has been pricing in since May.

The Q1 print was the catalyst for everything that followed — a 35% single-day gain and 53% five-day move on a historic beat. Wednesday's Q2 report will test whether that demand signal was a sustainable inflection or a one-quarter anomaly inflated by China export-window dynamics ahead of tighter restrictions.

Stocks in this article

See the live data behind this article on ORTEX.

Open AXTI on ORTEX →

How this article was generated

Generated
27 Jul 2026, 04:39
Data as of
27 Jul 2026, 03:54
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notesPrevious Mi Articles
Validation notes
  • soft: missing section mentions: short interest (informational only)

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.